Drugs /

ifx-hu2.0

Back to Drugs List

Overview

Trade Name(s):
Immunefx
NCI Definition [1]:
A whole cell cancer vaccine composed of irradiated autologous whole tumor cells that are transfected, ex vivo, with a plasmid DNA encoding the highly immunogenic Streptococcus pyogenes (S. pyogenes) bacterial antigen Emm55, with potential immunostimulating and antineoplastic activities. Upon intralesional administration of IFx-Hu2.0, the tumor cells expressing the Emm55 bacterial antigen on their cell surface are taken up and processed by antigen-presenting cells (APCs), thereby presenting both the Emm55 and the patient-specific tumor-associated antigens (TAAs) to the immune system. This activates the immune system to elicit a tumor antigen-specific cytotoxic T-lymphocyte (CTL)-mediated immune response against the tumor cells expressing the TAAs.

Clinical Trials

View Clinical Trials for ifx-hu2.0

Ifx-hu2.0 has been investigated in 2 clinical trials, of which 2 are open and 0 are closed. Of the trials investigating ifx-hu2.0, 2 are phase 1 (2 open).

Basal cell carcinoma and skin squamous cell carcinoma are the most common diseases being investigated in ifx-hu2.0 clinical trials [2].

Drug Details

Synonyms [2]:
autologous cancer cell-transfected with plasmid dna encoding for emm55 streptococcal antigen ifx-hu2.0, ImmuneFx, pdna autologous cancer cell vaccine ifx-hu2.0, pdna-encoding emm55 autologous cancer cell vaccine ifx-hu2.0, plasmid dna autologous cancer vaccine ifx-hu2.0, plasmid dna vaccine encoding s. pyogenes emm55 protein
NCIT ID [1]:
C157262

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.